TSHA
NASDAQ
$5.58
Taysha Gene Therapies Inc (TSHA)
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $13 (+132.97%)
Market Cap
$1.78B
Free Cash Flow Yield
-6.34%
Beta (5Y)
1.42
Price Chart
Valuation
Market Cap$1.78B
P/S238.09
P/B7.72
Profitability
Total Revenue (TTM)$7.47M
Gross Profit (TTM)$7.47M
EBITDA-$131M
Operating Margin-1774%
EPS-$0.46
Financial Health
Debt-to-Equity23.1%
Free Cash Flow Yield-6.34%
Growth & Risk
FCF 5Y CAGR+16.88%
Beta (5Y)1.42
Sharpe Ratio1.22